Dasiglucagon + Dasiglucagon + Placebo

Phase 2Withdrawn

0 views this week 0 watching💤 Quiet

Interest: 24/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypoglycemia

Conditions

Hypoglycemia, Glucose Metabolism Disorders

Trial Timeline

Feb 1, 2023 → Feb 1, 2023

NCT ID

NCT04824872

About Dasiglucagon + Dasiglucagon + Placebo

Dasiglucagon + Dasiglucagon + Placebo is a phase 2 stage product being developed by Zealand Pharma for Hypoglycemia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04824872. Target conditions include Hypoglycemia, Glucose Metabolism Disorders.

What happened to similar drugs?

2 of 14 similar drugs in Hypoglycemia were approved

Approved (2) Terminated (0) Active (12)

✅Sitagliptin phosphate + PlaceboMerckApproved

✅PramlintideBristol Myers SquibbApproved

🔄Nasal GlucagonEli LillyPhase 3

🔄DasiglucagonNovo NordiskPhase 3

🔄dasiglucagon + placebo + GlucaGen HypoKitZealand PharmaPhase 3

🔄Dasiglucagon + PlaceboZealand PharmaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04824872	Phase 2	Withdrawn	Feb 1, 2023	Feb 1, 2023	Hypoglycemia

Competing Products

20 competing products in Hypoglycemia

See all competitors

Product	Company	Stage	Hype Score
MBX 1416 (INN imapextide)	MBX Biosciences	Phase 2	36
MBX 1416 (Part A) + MBX 1416 (Part B) + Placebo + MBX 1416 (Part C)	MBX Biosciences	Phase 1	23
Nasal Glucagon	Eli Lilly	Phase 3	40
Glucagon + Insulin	Abvance Therapeutics	Phase 1	19
Nasal Glucagon + Intramuscular Glucagon	Eli Lilly	Phase 1	29
Nasal Glucagon 1 mg + Nasal Glucagon 2 mg + SC Glucagon + Nasal Glucagon 3 mg	Eli Lilly	Phase 2	35
Nasal Glucagon	Eli Lilly	Phase 3	40
Eplerenone + Placebo	Johnson & Johnson	Pre-clinical	26
Sitagliptin phosphate + Placebo	Merck	Approved	43
Pasireotide	Novartis	Phase 1	29
Dasiglucagon	Novo Nordisk	Phase 3	40
Glucagen + Mayne Glucagon	Pfizer	Phase 1	29
Pramlintide	Bristol Myers Squibb	Approved	43
dasiglucagon + placebo + GlucaGen HypoKit	Zealand Pharma	Phase 3	37
Dasiglucagon + Placebo	Zealand Pharma	Phase 1	26
ZP4207 + Glucagon	Zealand Pharma	Phase 1	26
ZP4207 + Placebo	Zealand Pharma	Phase 1	26
Dasiglucagon + Placebo	Zealand Pharma	Phase 3	37
dasiglucagon + GlucaGen	Zealand Pharma	Phase 3	37
Dasiglucagon + Placebo	Zealand Pharma	Phase 2	32